Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-Based vectors from stable producer cells

Thomas Relander, Maria Johansson, Karin Olsson, Yasuhiro Ikeda, Yasuhiro Takeuchi, Mary Collins, Johan Richter

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


A novel, stable human immunodeficiency virus type 1 vector packaging system, STAR, was tested for its ability to transduce human cord blood CD34+ progenitor cells assayed both in vitro and after transplantation into NOD/SCID mice. Vectors pseudotyped with three different gammaretrovirus envelopes were used: the amphotropic MLV envelope (MLV-A), a modified gibbon ape leukemia virus envelope (GALV+), and a modified feline endogenous virus RD114 envelope (RDpro). Gene transfer to freshly thawed CD34+ cells in the absence of cytokines was very low. Addition of cytokines increased gene transfer efficiency significantly and this was further augmented if the cells were prestimulated for 24 h. Concentration of the vectors (15-fold) by low-speed centrifugation increased gene transfer to CD34+ cells in vitro even further. More than 90% of cells were transduced with a single exposure to the RDpro vector as determined by GFP expression using flow cytometry. The two other pseudotypes transduced approximately 65-70% of the cells under the same conditions. Transplantation of CD34+ cells prestimulated for 24 h and then transduced with a single exposure to concentrated vector revealed that the RDpro vector transduced 55.1% of NOD/SCID repopulating human cells, which was significantly higher than the MLV-A (12.6%)- or GALV+ (25.1%)-pseudotyped vectors.

Original languageEnglish (US)
Pages (from-to)452-459
Number of pages8
JournalMolecular Therapy
Issue number3
StatePublished - Mar 2005


  • Amphotropic
  • GALV
  • GFP
  • Gene transfer
  • HIV-1
  • Hematopoietic
  • RD114

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Gene transfer to repopulating human CD34<sup>+</sup> cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-Based vectors from stable producer cells'. Together they form a unique fingerprint.

Cite this